Browse by author
Lookup NU author(s): Dr Philip Brown,
Dr Arthur Pratt,
Professor John IsaacsORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The treatment and outcomes of patients with rheumatoid arthritis ( RA) have been transformed over the past two decades. Low disease activity and remission are now frequently achieved, and this success is largely the result of the evolution of treatment paradigms and the introduction of new therapeutic agents. Despite the rapid pace of change, the most commonly used drug in RA remains methotrexate, which is considered the anchor drug for this condition. In this Review, we describe the known pharmacokinetic properties and putative mechanisms of action of methotrexate. Consideration of the pharmacodynamic perspective could inform the development of biomarkers of responsiveness to methotrexate, enabling therapy to be targeted to specific groups of patients. Such biomarkers could revolutionize the management of RA.
Author(s): Brown PM, Pratt AG, Isaacs JD
Publication type: Review
Publication status: Published
Journal: Nature Reviews Rheumatology
Print publication date: 01/12/2016
Online publication date: 27/10/2016
Acceptance date: 01/01/1900
ISSN (print): 1759-4790
ISSN (electronic): 1759-4804
Publisher: NATURE PUBLISHING GROUP